Osaka, Japan - December 9, 2021 - Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) today announced the listing of five generic drugs with nine strengths in the NHI (National Health Insurance) drug price list. Sawai’s product line now includes 331 compounds with 817 strengths.
The list of approved products
1. Levetiracetam Tablets, Granular Tablets, DS
| Generic name |
Levetiracetam |
| Strengths |
Tablets, Granular Tablets: 250 mg, 500 mg, DS: 50% |
| Brand products |
E Keppra® Tablets 250 mg, 500 mg, E Keppra® Dry syrup 50% |
2. Ambrisentan Tablets
| Generic name |
Ambrisentan |
| Strengths |
Tablets: 2.5 mg |
| Brand products |
Volibris Tablets 2.5 mg |
3. Olopatadine Ophthalmic Solution
| Generic name |
Olopatadine |
| Strengths |
Ophthalmic Solution: 0.1% |
| Brand products |
Patanol® Ophthalmic Solution 0.1% |
4. Iguratimod Tablets
| Generic name |
Iguratimod |
| Strengths |
Tablets: 25 mg |
| Brand products |
Careram® Tablets 25 mg |
5. Bortezomib Injection
| Generic name |
Bortezomib |
| Strengths |
Injection: 3 mg |
| Brand products |
VELCADE® Injection 3 mg |
The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.
